View in EDS

Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell Lymphoma.

Saved in:
Bibliographic Details
Title: Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell Lymphoma.
Authors: Wang S; Department of Hematology, Amsterdam UMC-Location Vrije Universiteit, Cancer Center Amsterdam, Amsterdam, The Netherlands.; Department of Pathology, Amsterdam UMC-Location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.; Divisions of Oncology and Hematology, Department of Medicine, Stanford University, Stanford, CA., Nijland M; University Medical Center Groningen, Groningen, The Netherlands., Strobbe L; Gelre Hospital, Zutphen, The Netherlands., Oosterveld M; Canisius Wilhelmina Hospital, Nijmegen, The Netherlands., Boersma R; Amphia Hospital, Breda, The Netherlands., Koene H; St Antonius Hospital, Utrecht, The Netherlands., Klerk C; Dijklander Hospital, Hoorn, The Netherlands., de Jongh E; Albert Schweitzer Hospital, Dordrecht, The Netherlands., Koster A; VieCuri Medical Center, Venlo, The Netherlands., Pruijt H; Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, The Netherlands., van der Poel M; Maastricht University Medical Center, Maastricht, The Netherlands., van Werkhoven E; Hemato-Oncology Foundation for Adults in The Netherlands (HOVON), Rotterdam, The Netherlands., Zanders H; Hemato-Oncology Foundation for Adults in The Netherlands (HOVON), Rotterdam, The Netherlands., Dinmohamed A; Netherlands Comprehensive Cancer Organization (IKNL), Enschede, The Netherlands., Pegtel M; Department of Pathology, Amsterdam UMC-Location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., Meek S; Foresight Diagnostics, Inc, Boulder, CO., Stowell SL; Foresight Diagnostics, Inc, Boulder, CO., Warinske H; Foresight Diagnostics, Inc, Boulder, CO., Alizadeh AA; Divisions of Oncology and Hematology, Department of Medicine, Stanford University, Stanford, CA., Kurtz DM; Foresight Diagnostics, Inc, Boulder, CO., Chamuleau MED; Department of Hematology, Amsterdam UMC-Location Vrije Universiteit, Cancer Center Amsterdam, Amsterdam, The Netherlands.
Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2026 Feb 10; Vol. 44 (5), pp. 400-409. Date of Electronic Publication: 2025 Dec 12.
Publication Type: Journal Article; Validation Study; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41385760
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell Lymphoma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Wang+S%22">Wang S</searchLink>; Department of Hematology, Amsterdam UMC-Location Vrije Universiteit, Cancer Center Amsterdam, Amsterdam, The Netherlands.; Department of Pathology, Amsterdam UMC-Location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.; Divisions of Oncology and Hematology, Department of Medicine, Stanford University, Stanford, CA.<br /><searchLink fieldCode="AU" term="%22Nijland+M%22">Nijland M</searchLink>; University Medical Center Groningen, Groningen, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Strobbe+L%22">Strobbe L</searchLink>; Gelre Hospital, Zutphen, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Oosterveld+M%22">Oosterveld M</searchLink>; Canisius Wilhelmina Hospital, Nijmegen, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Boersma+R%22">Boersma R</searchLink>; Amphia Hospital, Breda, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Koene+H%22">Koene H</searchLink>; St Antonius Hospital, Utrecht, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Klerk+C%22">Klerk C</searchLink>; Dijklander Hospital, Hoorn, The Netherlands.<br /><searchLink fieldCode="AU" term="%22de+Jongh+E%22">de Jongh E</searchLink>; Albert Schweitzer Hospital, Dordrecht, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Koster+A%22">Koster A</searchLink>; VieCuri Medical Center, Venlo, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Pruijt+H%22">Pruijt H</searchLink>; Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, The Netherlands.<br /><searchLink fieldCode="AU" term="%22van+der+Poel+M%22">van der Poel M</searchLink>; Maastricht University Medical Center, Maastricht, The Netherlands.<br /><searchLink fieldCode="AU" term="%22van+Werkhoven+E%22">van Werkhoven E</searchLink>; Hemato-Oncology Foundation for Adults in The Netherlands (HOVON), Rotterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Zanders+H%22">Zanders H</searchLink>; Hemato-Oncology Foundation for Adults in The Netherlands (HOVON), Rotterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Dinmohamed+A%22">Dinmohamed A</searchLink>; Netherlands Comprehensive Cancer Organization (IKNL), Enschede, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Pegtel+M%22">Pegtel M</searchLink>; Department of Pathology, Amsterdam UMC-Location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Meek+S%22">Meek S</searchLink>; Foresight Diagnostics, Inc, Boulder, CO.<br /><searchLink fieldCode="AU" term="%22Stowell+SL%22">Stowell SL</searchLink>; Foresight Diagnostics, Inc, Boulder, CO.<br /><searchLink fieldCode="AU" term="%22Warinske+H%22">Warinske H</searchLink>; Foresight Diagnostics, Inc, Boulder, CO.<br /><searchLink fieldCode="AU" term="%22Alizadeh+AA%22">Alizadeh AA</searchLink>; Divisions of Oncology and Hematology, Department of Medicine, Stanford University, Stanford, CA.<br /><searchLink fieldCode="AU" term="%22Kurtz+DM%22">Kurtz DM</searchLink>; Foresight Diagnostics, Inc, Boulder, CO.<br /><searchLink fieldCode="AU" term="%22Chamuleau+MED%22">Chamuleau MED</searchLink>; Department of Hematology, Amsterdam UMC-Location Vrije Universiteit, Cancer Center Amsterdam, Amsterdam, The Netherlands.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228309333%22">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</searchLink> [J Clin Oncol] 2026 Feb 10; Vol. 44 (5), pp. 400-409. <i>Date of Electronic Publication: </i>2025 Dec 12.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Validation Study; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Society+of+Clinical+Oncology%22">American Society of Clinical Oncology </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>8309333 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1527-7755 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%220732183X%22">0732183X </searchLink><i>NLM ISO Abbreviation: </i>J Clin Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41385760
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1200/JCO-25-01712
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 400
    Titles:
      – TitleFull: Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell Lymphoma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Wang S
      – PersonEntity:
          Name:
            NameFull: Nijland M
      – PersonEntity:
          Name:
            NameFull: Strobbe L
      – PersonEntity:
          Name:
            NameFull: Oosterveld M
      – PersonEntity:
          Name:
            NameFull: Boersma R
      – PersonEntity:
          Name:
            NameFull: Koene H
      – PersonEntity:
          Name:
            NameFull: Klerk C
      – PersonEntity:
          Name:
            NameFull: de Jongh E
      – PersonEntity:
          Name:
            NameFull: Koster A
      – PersonEntity:
          Name:
            NameFull: Pruijt H
      – PersonEntity:
          Name:
            NameFull: van der Poel M
      – PersonEntity:
          Name:
            NameFull: van Werkhoven E
      – PersonEntity:
          Name:
            NameFull: Zanders H
      – PersonEntity:
          Name:
            NameFull: Dinmohamed A
      – PersonEntity:
          Name:
            NameFull: Pegtel M
      – PersonEntity:
          Name:
            NameFull: Meek S
      – PersonEntity:
          Name:
            NameFull: Stowell SL
      – PersonEntity:
          Name:
            NameFull: Warinske H
      – PersonEntity:
          Name:
            NameFull: Alizadeh AA
      – PersonEntity:
          Name:
            NameFull: Kurtz DM
      – PersonEntity:
          Name:
            NameFull: Chamuleau MED
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 10
              M: 02
              Text: 2026 Feb 10
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1527-7755
          Numbering:
            – Type: volume
              Value: 44
            – Type: issue
              Value: 5
          Titles:
            – TitleFull: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
              Type: main
ResultId 1